NovaBridge Biosciences Increase (Decrease) in Contract with Customer, Liability
NovaBridge Biosciences (NBP) reported Increase (Decrease) in Contract with Customer, Liability of CNY 17.77 million for the 12-month period ending 2023-12-31, per its 20-F filed 2024-04-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2024-04-30
CNY
| Period end | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|
| 2023-12-31 | 17.77M CNY 20-F · filed 2024-04-30 | |
| 2022-12-31 | 52.55M CNY 20-F · filed 2024-04-30 | |
| 2022-06-30 | 16.01M CNY 6-K · filed 2022-11-10 | |
| 2021-12-31 | 224.00M CNY 20-F · filed 2024-04-30 | |
| 2018-12-31 | -15.80M CNY 20-F · filed 2021-04-28 | |
| 2017-12-31 | 15.80M CNY 20-F · filed 2020-04-29 |
USD
| Period end | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|
| 2023-12-31 | $2.50M 20-F · filed 2024-04-30 | |
| 2022-12-31 | $7.62M 20-F · filed 2023-05-01 | |
| 2022-06-30 | $2.39M 6-K · filed 2022-11-10 | |
| 2021-12-31 | $35.15M 20-F · filed 2022-04-29 |